Detalles de la búsqueda
1.
A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics.
Child Psychiatry Hum Dev
; 54(5): 1360-1372, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35292925
2.
Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies.
Autism Res
; 16(10): 2021-2034, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37794745
3.
Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
J Autism Dev Disord
; 51(8): 2959-2972, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33151500
4.
Efficacy of Tianeptine 25-50 mg in Elderly Patients With Recurrent Major Depressive Disorder: An 8-Week Placebo- and Escitalopram-Controlled Study.
J Clin Psychiatry
; 79(4)2018 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29995359
5.
Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
J Autism Dev Disord
; 51(8): 2973, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33423216
Resultados
1 -
5
de 5
1
Próxima >
>>